Akèy › Kansè nan tete › Florid › Orlando
Etid klinik pou Kansè nan tete nan Orlando, FL
23 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Orlando (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Advent Health, Orlando
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- AdventHealth Medical Group Oncology Research at Celebration, Kissimmee · 16 mi lwen
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Ap rekriteFaz 3
- AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0024), Altamonte Springs · 9 mi lwen
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044), Altamonte Springs · 9 mi lwen
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ap rekriteFaz 3
- Orlando Health Cancer Institute ( Site 0011), Orlando
- AdventHealth Altamonte Springs ( Site 0021), Altamonte Springs · 9 mi lwen
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Ap rekriteFaz 3
- Research Site, Altamonte Springs · 9 mi lwen
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- AdventHealth Altamonte Springs, Altamonte Springs · 9 mi lwen
- Clermont Oncology Center, Clermont · 24 mi lwen
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Ap rekriteFaz 2
- AdventHealth Altamonte Springs, Altamonte Springs · 9 mi lwen
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Ap rekriteFaz 1/2
- Florida Cancer Specialists - Lake Nona, Orlando
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- AdventHealth Orlando Infusion Center, Orlando
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute - Lake Nona Florida, Orlando
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
Ap rekriteFaz 1
- Cancer Centers of Florida, Ocoee · 10 mi lwen
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- AdventHealth, Altamonte Springs · 9 mi lwen
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- AdventHealth Orlando, Orlando
- Orlando Health Cancer Institute, Orlando
- AdventHealth Altamonte, Altamonte Springs · 9 mi lwen
- ak 1 plis
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Ap rekriteFaz 3
- Advent Health - Orlando, Orlando
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- AdventHealth Orlando, Orlando
- Orlando Health Cancer Institute, Orlando
- AdventHealth Altamonte, Altamonte Springs · 9 mi lwen
- ak 1 plis
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Ap rekriteFaz 1/2
- Florida Cancer Specialists, Orlando
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Ap rekriteEtid obsèvasyon
- AdventHealth East Altamonte Oncology and Hematology, Altamonte Springs · 9 mi lwen
Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Adventhealth, Orlando
UCF MammoChat: Image Repository
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- University of Central Florida, Orlando
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Ap rekriteFaz 1
- Florida Cancer Specialists, Orlando
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #8, Orlando
Etid Kansè nan tete nan lòt vil
- New York City, NY134 etid
- Houston, TX126 etid
- Boston, MA111 etid
- Nashville, TN80 etid
- Los Angeles, CA72 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Durham, NC63 etid
- Queens, NY63 etid
- Chicago, IL58 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Orlando
- Kansè Poumon ki pa ti selil44 etid
- Obèsite31 etid
- Kansè Metastatik29 etid
- Sipwa27 etid
- Maladi Alzheimer25 etid
- Dyabèt Tip 224 etid
- Kansè (tout kalite)24 etid
- Kansè ovè22 etid
- Kolit Ulseratif22 etid
- Kansè poumon21 etid
- Kansè kolorektal19 etid
- Twoub depresif majè19 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.